Skip to main content
Top
Published in: International Urology and Nephrology 1/2010

01-03-2010 | Nephrology - Original Paper

The factors that affect plasma homocysteine levels, pulse wave velocity and their relationship with cardiovascular disease indicators in peritoneal dialysis patients

Authors: Sibel Ertek, Ayse Nur Torun, Kenan Ates

Published in: International Urology and Nephrology | Issue 1/2010

Login to get access

Abstract

Objective

The incidence of cardiovascular diseases (CVD) is high in end-stage renal disease (ESRD) population and hyperhomocysteinemia is an important CVD risk factor. The aims of this study are to asses the incidence of hyperhomocysteinemia and the factors that affect the homocysteine (Hcy) levels in peritoneal dialysis (PD) patients, and to analyze the relationships between Hcy levels and clinical and echocardiographic CVD, and the pulse wave velocity (PWV).

Study design

Sixty ESRD patients undergoing PD for at least 6 months were included in the study. Biochemical parameters, echocardiography, and PWV were analysed for every subject.

Results

Mean Hcy level was 27.2 ± 15.7 μmol/L and was high in 53 patients (88.3%). Fibrinogen, dialysate/plasma creatinine ratio and folic acid were found to be the independent predictors of Hcy level (P < 0.001; P < 0.01; P < 0.05, respectively). Patients with atherosclerosis had significantly higher plasma Hcy levels (P < 0.05). No significant relationship was found between plasma Hcy levels and echocardiographic findings and PWV.

Conclusion

Hyperhomocysteinemia incidence seems high among PD patients and despite significant relationship between fibrinogen and Hcy in our study, it is essential to evaluate the link between Hcy levels and inflammation. Folic acid replacement even in normal folic acid levels, enough elimination of volume and solutes may be beneficial to control Hcy levels, whereas PWV was found to be related with comorbidities and and dialysate kinetics.
Literature
1.
go back to reference Levin A (2003) Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial 16:101–105CrossRefPubMed Levin A (2003) Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial 16:101–105CrossRefPubMed
2.
go back to reference Sarnak MJ, Levey AS (1999) Epidemiology of cardiac disease in dialysis patients. Semin Dial 12:69–76CrossRef Sarnak MJ, Levey AS (1999) Epidemiology of cardiac disease in dialysis patients. Semin Dial 12:69–76CrossRef
3.
go back to reference Remppis A, Ritz E (2008) Cardiac problems in the dialysis patient: beyond coronary disease. Semin Dial 21:319–325CrossRefPubMed Remppis A, Ritz E (2008) Cardiac problems in the dialysis patient: beyond coronary disease. Semin Dial 21:319–325CrossRefPubMed
4.
go back to reference Herrmann W, Herrmann M, Obeid R (2007) Hyperhomocysteinaemia: a critical review of old and new aspects. Curr Drug Metab 8:17–31CrossRefPubMed Herrmann W, Herrmann M, Obeid R (2007) Hyperhomocysteinaemia: a critical review of old and new aspects. Curr Drug Metab 8:17–31CrossRefPubMed
5.
go back to reference Clarke R, Daly L, Robinson K et al (1991) Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324:1149–1155PubMed Clarke R, Daly L, Robinson K et al (1991) Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324:1149–1155PubMed
7.
go back to reference Hultberg B, Andersson A, Sterner G (1993) Plasma homocysteine in renal failure. Clin Nephrol 40:230–234PubMed Hultberg B, Andersson A, Sterner G (1993) Plasma homocysteine in renal failure. Clin Nephrol 40:230–234PubMed
8.
go back to reference Moustapha A, Gupta A, Robinson K et al (1999) Prevalance and determinants of hyper-homocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int 55:1470–1475CrossRefPubMed Moustapha A, Gupta A, Robinson K et al (1999) Prevalance and determinants of hyper-homocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int 55:1470–1475CrossRefPubMed
9.
go back to reference Chauveau P, Chadefaux B, Coude M et al (1993) Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int Suppl 41:S72–S77PubMed Chauveau P, Chadefaux B, Coude M et al (1993) Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int Suppl 41:S72–S77PubMed
10.
go back to reference Robinson K, Gupta A, Dennis V et al (1996) Hyper-homocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94:2743–2748PubMed Robinson K, Gupta A, Dennis V et al (1996) Hyper-homocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94:2743–2748PubMed
11.
go back to reference Fodinger M, Buchmayer H, Heinz G et al (2001) Association of two MTHFR polymorphisms with total homcysteine plasma levels in dialysis patients. Am J Kidney Dis 38:77–84CrossRefPubMed Fodinger M, Buchmayer H, Heinz G et al (2001) Association of two MTHFR polymorphisms with total homcysteine plasma levels in dialysis patients. Am J Kidney Dis 38:77–84CrossRefPubMed
12.
go back to reference Morimoto K, Haneda T, Okamoto K, Ishida H, Kikuchi K (2002) Methylene-tetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia, and cardiovascular diseases in chronic hemodialysis patients. Nephon 90:43–50CrossRef Morimoto K, Haneda T, Okamoto K, Ishida H, Kikuchi K (2002) Methylene-tetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia, and cardiovascular diseases in chronic hemodialysis patients. Nephon 90:43–50CrossRef
13.
go back to reference Gelev S, Spasovski G, Dzikova S, Trajkovski Z, Damjanovski G, Amitov V, Sikole A (2008) Vascular calcification and atherosclerosis in hemodialysis patients: what can we learn from the routine clinical practice? Int Urol Nephrol 40:763–770 (Epub 2008 Jun 27)CrossRefPubMed Gelev S, Spasovski G, Dzikova S, Trajkovski Z, Damjanovski G, Amitov V, Sikole A (2008) Vascular calcification and atherosclerosis in hemodialysis patients: what can we learn from the routine clinical practice? Int Urol Nephrol 40:763–770 (Epub 2008 Jun 27)CrossRefPubMed
14.
go back to reference Kocak H, Gumuslu S, Sahin E et al (2009) Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in peritoneal dialysis patients. Int Urol Nephrol 41:409–416 (Epub 2008 Dec 30)CrossRefPubMed Kocak H, Gumuslu S, Sahin E et al (2009) Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in peritoneal dialysis patients. Int Urol Nephrol 41:409–416 (Epub 2008 Dec 30)CrossRefPubMed
15.
go back to reference Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM (1999) Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99:2434–2439PubMed Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM (1999) Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99:2434–2439PubMed
16.
go back to reference Cohn JN, Quyyumi AA, Holberg NK, Jamerson KA (2004) Surrogate markers for cardiovascular disease: functional markers. Circulation 109(25 Suppl 1):IV31–IV46PubMed Cohn JN, Quyyumi AA, Holberg NK, Jamerson KA (2004) Surrogate markers for cardiovascular disease: functional markers. Circulation 109(25 Suppl 1):IV31–IV46PubMed
17.
go back to reference London GM, Marchais SJ, Safar ME, Genest AP, Metivier F, Chedid K, London AM (1990) Aortic and large artery compliance in end-stage renal disease. Kidney Int 37:137–142CrossRefPubMed London GM, Marchais SJ, Safar ME, Genest AP, Metivier F, Chedid K, London AM (1990) Aortic and large artery compliance in end-stage renal disease. Kidney Int 37:137–142CrossRefPubMed
18.
go back to reference Du Bois D, Du Bois EF (1989) A formula to estimate the approximate surface area if height and weight be known.1916. Nutrition 5:303–311PubMed Du Bois D, Du Bois EF (1989) A formula to estimate the approximate surface area if height and weight be known.1916. Nutrition 5:303–311PubMed
19.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373–383CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373–383CrossRefPubMed
20.
go back to reference Refsum H, Fisherstrand T, Guttormsen AB, Ueland PM (1997) Assessment of homocyteine status. J Inherit Metab Dis 20:286–294CrossRefPubMed Refsum H, Fisherstrand T, Guttormsen AB, Ueland PM (1997) Assessment of homocyteine status. J Inherit Metab Dis 20:286–294CrossRefPubMed
21.
go back to reference Still RA, McDowell IF (1998) Clinical implications of plasma homocysteine measurement in cardiovascular disease. J Clin Pathol 51:183–188CrossRefPubMed Still RA, McDowell IF (1998) Clinical implications of plasma homocysteine measurement in cardiovascular disease. J Clin Pathol 51:183–188CrossRefPubMed
22.
go back to reference Sahn DJ, DeMaria A, Kisslo J, Weyman A (1978) The committee on M-mode standardization of the American society of echocardiography. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58:1072–1083PubMed Sahn DJ, DeMaria A, Kisslo J, Weyman A (1978) The committee on M-mode standardization of the American society of echocardiography. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58:1072–1083PubMed
23.
go back to reference Bostom AG, Culleton BF (1999) Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 10:891–900PubMed Bostom AG, Culleton BF (1999) Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 10:891–900PubMed
24.
go back to reference Chrysohoou C, Panagiotakos DB, Pitsavos C et al (2004) The associations between smoking, physical activity, dietary habits and plasma homocysteine levels in cardiovascular disease free people: the ‘ATTICA’ study. Vasc Med 9:117–123CrossRefPubMed Chrysohoou C, Panagiotakos DB, Pitsavos C et al (2004) The associations between smoking, physical activity, dietary habits and plasma homocysteine levels in cardiovascular disease free people: the ‘ATTICA’ study. Vasc Med 9:117–123CrossRefPubMed
25.
go back to reference Sobczak A, Wardas W, Zielinska-Danch W, Pawlicki K (2004) The influence of smoking on plasma homocysteine and cysteine levels in passive and active smokers. Clin Chem Lab Med 42:408–414CrossRefPubMed Sobczak A, Wardas W, Zielinska-Danch W, Pawlicki K (2004) The influence of smoking on plasma homocysteine and cysteine levels in passive and active smokers. Clin Chem Lab Med 42:408–414CrossRefPubMed
26.
go back to reference Tayama J, Munakata M, Yoshinaga K, Toyota T (2006) Higher plasma homocysteine concentration ia associated with more advanced ischemic arterial stiffness and greater blood pressure response to stress in hypertensive patients. Hypertens Res 29:403–409CrossRefPubMed Tayama J, Munakata M, Yoshinaga K, Toyota T (2006) Higher plasma homocysteine concentration ia associated with more advanced ischemic arterial stiffness and greater blood pressure response to stress in hypertensive patients. Hypertens Res 29:403–409CrossRefPubMed
27.
go back to reference Coban E, Ozdogan M, ErmiS C (2004) Plasma levels of homocysteine in patients with white-coat hypertension. Int J Clin Pract 58:997–999CrossRefPubMed Coban E, Ozdogan M, ErmiS C (2004) Plasma levels of homocysteine in patients with white-coat hypertension. Int J Clin Pract 58:997–999CrossRefPubMed
28.
go back to reference Stehouwer CD, van Guldener C (2003) Does homocysteine cause hypertension? Clin Chem Lab Med 41:1408–1411CrossRefPubMed Stehouwer CD, van Guldener C (2003) Does homocysteine cause hypertension? Clin Chem Lab Med 41:1408–1411CrossRefPubMed
29.
go back to reference Aso Y, Yoshida N, Okumura K et al (2004) Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia. Clin Chim Acta 348:139–145CrossRefPubMed Aso Y, Yoshida N, Okumura K et al (2004) Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia. Clin Chim Acta 348:139–145CrossRefPubMed
30.
31.
go back to reference Peeters AC, van Aken BE, Blom HJ, Reitsma PH (2007) den Heijer M (2007) The effect of homocysteine reduction by B-vitamin supplementation on inflammatory markers. Clin Chem Lab Med 45:47–53CrossRef Peeters AC, van Aken BE, Blom HJ, Reitsma PH (2007) den Heijer M (2007) The effect of homocysteine reduction by B-vitamin supplementation on inflammatory markers. Clin Chem Lab Med 45:47–53CrossRef
32.
go back to reference Schernthaner GH, Plank C, Minar E, Bieglmayer C, Koppensteiner R (2006) Schernthaner G (2006) No effect of homocysteine lowering therapy on vascular inflammation and haemostasis in peripheral arterial occlusive disease. Eur J Clin Invest 36:333–339CrossRefPubMed Schernthaner GH, Plank C, Minar E, Bieglmayer C, Koppensteiner R (2006) Schernthaner G (2006) No effect of homocysteine lowering therapy on vascular inflammation and haemostasis in peripheral arterial occlusive disease. Eur J Clin Invest 36:333–339CrossRefPubMed
33.
go back to reference McGregor D, Shand B, Lynn K (2000) A controlled trial of the effect of folate supplements on homocysteine, lipids and hemorheology in end-stage renal disease. Nephron 85:215–220CrossRefPubMed McGregor D, Shand B, Lynn K (2000) A controlled trial of the effect of folate supplements on homocysteine, lipids and hemorheology in end-stage renal disease. Nephron 85:215–220CrossRefPubMed
34.
go back to reference Alvares Delfino VD, de Andrade Vianna AC, Mocelin AJ, Barbosa DS, Mise RA, Matsuo T (2007) Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients. Nutiriton 23:242–247 Alvares Delfino VD, de Andrade Vianna AC, Mocelin AJ, Barbosa DS, Mise RA, Matsuo T (2007) Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients. Nutiriton 23:242–247
35.
go back to reference Hirose S, Kono R, Mitarai T, Isoda K, Kim S, Shimoyama H (1999) Hyper-homocysteinemia in CAPD patients: peritoneal transport of total homocysteine at peritoneal equilibration test and daily elimination of total homocysteine. Nippon Jinzo Gakkai Shi 41:778–786PubMed Hirose S, Kono R, Mitarai T, Isoda K, Kim S, Shimoyama H (1999) Hyper-homocysteinemia in CAPD patients: peritoneal transport of total homocysteine at peritoneal equilibration test and daily elimination of total homocysteine. Nippon Jinzo Gakkai Shi 41:778–786PubMed
36.
go back to reference Vychytil A, Fodinger M, Papagiannopoulos M, Wölfl G, Hörl WH, Sunder-Plassmann G (1999) Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients. Kidney Int 55:2054–2061CrossRefPubMed Vychytil A, Fodinger M, Papagiannopoulos M, Wölfl G, Hörl WH, Sunder-Plassmann G (1999) Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients. Kidney Int 55:2054–2061CrossRefPubMed
37.
go back to reference Churchill DN, Taylor DW, Keshaviah PR, The Canada-USA (CANUSA) Peritoneal Dialysis Study Group (1996) Adequacy of dialysis and nutrition in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 7:198–207 Churchill DN, Taylor DW, Keshaviah PR, The Canada-USA (CANUSA) Peritoneal Dialysis Study Group (1996) Adequacy of dialysis and nutrition in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 7:198–207
38.
go back to reference Johnson DW, Kay TD, Vesey DA, Isbel N, Campbell SB, Hawley CM (2000) Peritoneal homocysteine clearance is inefficient in peritoneal dialysis patients. Perit Dial Int 20:766–771PubMed Johnson DW, Kay TD, Vesey DA, Isbel N, Campbell SB, Hawley CM (2000) Peritoneal homocysteine clearance is inefficient in peritoneal dialysis patients. Perit Dial Int 20:766–771PubMed
40.
go back to reference Sydow K, Hornig B, Arakawa N et al (2004) Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA. Vasc Med 9:93–101CrossRefPubMed Sydow K, Hornig B, Arakawa N et al (2004) Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA. Vasc Med 9:93–101CrossRefPubMed
41.
go back to reference Cesari M, Zanchetta M, Burlina A et al (2005) Hyperhomocysteinemia is inversely related with left ventricular ejection fraction and predicts cardiovascular mortality in high risk coronary artery disease hypertensives. Arterioscler Thromb Vasc Biol 25:115–121PubMed Cesari M, Zanchetta M, Burlina A et al (2005) Hyperhomocysteinemia is inversely related with left ventricular ejection fraction and predicts cardiovascular mortality in high risk coronary artery disease hypertensives. Arterioscler Thromb Vasc Biol 25:115–121PubMed
42.
go back to reference Laurent S, Boutouyrie P, Asmar R et al (2001) Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37:1236–1241PubMed Laurent S, Boutouyrie P, Asmar R et al (2001) Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37:1236–1241PubMed
43.
go back to reference Blacher J, Demuth K, Guerin AP, Safar ME, Moatti N, London GM (1998) Influence of biochemical alterations on arterial stifness in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 18:535–541PubMed Blacher J, Demuth K, Guerin AP, Safar ME, Moatti N, London GM (1998) Influence of biochemical alterations on arterial stifness in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 18:535–541PubMed
44.
go back to reference Zoungas S, Branley P, Kerr PG et al (2004) Aterosclerosis and folic acid supplementation trial in chronic renal failure: baseline results. Nephrology (Carlton) 9:130–141CrossRef Zoungas S, Branley P, Kerr PG et al (2004) Aterosclerosis and folic acid supplementation trial in chronic renal failure: baseline results. Nephrology (Carlton) 9:130–141CrossRef
45.
go back to reference Bortolotto LA, Safar ME, Billaud E et al (1999) Plasma homocysteine, aortic stiffness, and renal function in hypertensive patients. Hypertension 34:837–842PubMed Bortolotto LA, Safar ME, Billaud E et al (1999) Plasma homocysteine, aortic stiffness, and renal function in hypertensive patients. Hypertension 34:837–842PubMed
46.
go back to reference Woodside JV, McMahon R, Gallagher AM et al (2004) Total homocysteine is not a determinant of arterial pulse wave velocity in young healthy adults. Atherosclerosis 177:337–344CrossRefPubMed Woodside JV, McMahon R, Gallagher AM et al (2004) Total homocysteine is not a determinant of arterial pulse wave velocity in young healthy adults. Atherosclerosis 177:337–344CrossRefPubMed
Metadata
Title
The factors that affect plasma homocysteine levels, pulse wave velocity and their relationship with cardiovascular disease indicators in peritoneal dialysis patients
Authors
Sibel Ertek
Ayse Nur Torun
Kenan Ates
Publication date
01-03-2010
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 1/2010
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-009-9625-y

Other articles of this Issue 1/2010

International Urology and Nephrology 1/2010 Go to the issue